Laurie S. Conklin
Children's National Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Laurie S. Conklin.
Immunity | 2014
Dror S. Shouval; Amlan Biswas; Jeremy A. Goettel; Katelyn McCann; Evan Conaway; Naresh Singh Redhu; Ivan D. Mascanfroni; Ziad Al Adham; Sydney Lavoie; Mouna Ibourk; Deanna D. Nguyen; Janneke N. Samsom; Johanna C. Escher; Raz Somech; Batia Weiss; Rita Beier; Laurie S. Conklin; Christen L. Ebens; Fernanda Stephanie Santos; Alexandre Rodrigues Ferreira; Mary Sherlock; Atul K. Bhan; Werner Müller; J. Rodrigo Mora; Francisco J. Quintana; Christoph Klein; Aleixo M. Muise; Bruce H. Horwitz; Scott B. Snapper
Intact interleukin-10 receptor (IL-10R) signaling on effector and T regulatory (Treg) cells are each independently required to maintain immune tolerance. Here we show that IL-10 sensing by innate immune cells, independent of its effects on T cells, was critical for regulating mucosal homeostasis. Following wild-type (WT) CD4(+) T cell transfer, Rag2(-/-)Il10rb(-/-) mice developed severe colitis in association with profound defects in generation and function of Treg cells. Moreover, loss of IL-10R signaling impaired the generation and function of anti-inflammatory intestinal and bone-marrow-derived macrophages and their ability to secrete IL-10. Importantly, transfer of WT but not Il10rb(-/-) anti-inflammatory macrophages ameliorated colitis induction by WT CD4(+) T cells in Rag2(-/-)Il10rb(-/-) mice. Similar alterations in the generation and function of anti-inflammatory macrophages were observed in IL-10R-deficient patients with very early onset inflammatory bowel disease. Collectively, our studies define innate immune IL-10R signaling as a key factor regulating mucosal immune homeostasis in mice and humans.
Bioconjugate Chemistry | 2014
Matthieu F. Dumont; Hilary A. Hoffman; Pryscilla R. S. Yoon; Laurie S. Conklin; Shanta Saha; Johnpierre Paglione; Raymond W. Sze; Rohan Fernandes
Molecular imaging agents enable the visualization of phenomena with cellular and subcellular level resolutions and therefore have enormous potential in improving disease diagnosis and therapy assessment. In this article, we describe the synthesis, characterization, and demonstration of core-shell, biofunctionalized, gadolinium-containing Prussian blue nanoparticles as multimodal molecular imaging agents. Our multimodal nanoparticles combine the advantages of MRI and fluorescence. The core of our nanoparticles consists of a Prussian blue lattice with gadolinium ions located within the lattice interstices that confer high relaxivity to the nanoparticles providing MRI contrast. The relaxivities of our nanoparticles are nearly nine times those observed for the clinically used Magnevist. The nanoparticle MRI core is biofunctionalized with a layer of fluorescently labeled avidin that enables fluorescence imaging. Biotinylated antibodies are attached to the surface avidin and confer molecular specificity to the nanoparticles by targeting cell-specific biomarkers. We demonstrate our nanoparticles as multimodal molecular imaging agents in an in vitro model consisting of a mixture of eosinophilic cells and squamous epithelial cells. Our nanoparticles specifically detect eosinophilic cells and not squamous epithelial cells, via both fluorescence imaging and MRI in vitro. These results suggest the potential of our biofunctionalized Prussian blue nanoparticles as multimodal molecular imaging agents in vivo.
Expert Review of Gastroenterology & Hepatology | 2010
Laurie S. Conklin; Maria Oliva-Hemker
Nutrition is a critical part of the management of inflammatory bowel disease (IBD) in children and adults. Malnutrition and micronutrient deficiencies are common at the time of diagnosis and may persist throughout the course of the disease. There are a number of similarities with regards to the nutritional complications and the approach to nutritional management in IBD in both children and adults, but there are also important differences. Growth failure, pubertal delay and the need for corticosteroid-sparing regimens are of higher importance in pediatrics. In the pediatric population, exclusive enteral nutrition may be equivalent to corticosteroids in inducing remission in acute Crohn’s disease, and may have benefits over corticosteroids in children. Adherence with exclusive enteral nutrition is better in children than in adults. Iron deficiency anemia is an important problem for adults and children with IBD. Intravenous iron administration may be superior to oral iron supplementation. Ensuring adequate bone health is another critical component of nutritional management in IBD, but guidelines for screening and therapeutic interventions for low bone mineral density are lacking in children.
Nature Reviews Gastroenterology & Hepatology | 2010
Laurie S. Conklin; Bernard Cohen; Lindsay Wilson; Carmen Cuffari; Maria Oliva-Hemker
Background. A 17-year-old white male with Crohns disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.Investigations. Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.Diagnosis. Anti-TNF-agent induced psoriasiform skin rash.Management. Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.
Scientific Reports | 2016
Yetrib Hathout; Laurie S. Conklin; Haeri Seol; Heather Gordish-Dressman; Kristy J. Brown; Lauren P. Morgenroth; Kanneboyina Nagaraju; Christopher R. Heier; Jesse M. Damsker; John N. van den Anker; Erik Henricson; Paula R. Clemens; Jean K. Mah; Craig M. McDonald; Eric P. Hoffman
Corticosteroids are extensively used in pediatrics, yet the burden of side effects is significant. Availability of a simple, fast, and reliable biochemical read out of steroidal drug pharmacodynamics could enable a rapid and objective assessment of safety and efficacy of corticosteroids and aid development of corticosteroid replacement drugs. To identify potential corticosteroid responsive biomarkers we performed proteome profiling of serum samples from DMD and IBD patients with and without corticosteroid treatment using SOMAscan aptamer panel testing 1,129 proteins in <0.1 cc of sera. Ten pro-inflammatory proteins were elevated in untreated patients and suppressed by corticosteroids (MMP12, IL22RA2, CCL22, IGFBP2, FCER2, LY9, ITGa1/b1, LTa1/b2, ANGPT2 and FGG). These are candidate biomarkers for anti-inflammatory efficacy of corticosteroids. Known safety concerns were validated, including elevated non-fasting insulin (insulin resistance), and elevated angiotensinogen (salt retention). These were extended by new candidates for metabolism disturbances (leptin, afamin), stunting of growth (growth hormone binding protein), and connective tissue remodeling (MMP3). Significant suppression of multiple adrenal steroid hormones was also seen in treated children (reductions of 17-hydroxyprogesterone, corticosterone, 11-deoxycortisol and testosterone). A panel of new pharmacodynamic biomarkers for corticosteroids in children was defined. Future studies will need to bridge specific biomarkers to mechanism of drug action, and specific clinical outcomes.
Clinical and translational gastroenterology | 2016
Christopher R. Heier; Alyson A. Fiorillo; Ellen Chaisson; Heather Gordish-Dressman; Yetrib Hathout; Jesse M. Damsker; Eric P. Hoffman; Laurie S. Conklin
Objective:Serum biomarkers may serve to predict early response to therapy, identify relapse, and facilitate drug development in inflammatory bowel disease (IBD). Biomarkers are particularly important in children, in whom achieving early remission and minimizing procedures are especially beneficial.Methods:We profiled protein and micro RNA (miRNA) in serum from patients pre- and post-therapy, to identify molecular markers of pharmacodynamic effect. Serum was obtained from children with IBD before and after treatment with either corticosteroids (prednisone; n=12) or anti-tumor necrosis factor-α biologic (infliximab; n=7). Over 1,100 serum proteins were assayed using aptamer-based SOMAscan proteomics, and 22 miRNAs analyzed by quantitative real time PCR. Concordance of longitudinal changes between the groups was used to identify markers responsive to treatment. Bioinformatic analysis was used to build insight into mechanisms of changes in response to treatment.Results:We identified 18 proteins and three miRNAs responsive to both prednisone and infliximab. Eight markers that decreased are associated with inflammation and have gene promoters regulated by nuclear factor (NF)-κB. Several that increased are associated with resolving inflammation and tissue damage. We also identified six markers that appear to be steroid-specific, three of which have glucocorticoid receptor binding elements in their promoter region.Conclusions:Serum markers regulated by the inflammatory transcription factor NF-κB are potential candidates for pharmacodynamic biomarkers that, if correlated with later outcomes like endoscopic or histologic healing, could be used to monitor treatment, optimize dosing, and enhance drug development. The pharmacodynamic biomarkers identified here hold potential to improve both clinical care and drug development. Further studies are warranted to investigate these markers as early predictors of response, or possibly surrogate outcomes.
Journal of Digestive Diseases | 2012
Laurie S. Conklin; Carmen Cuffari; Toshihiko Okazaki; Yinglei Miao; Bahman Saatian; Tian-E. Chen; Ming Tse; Steven R. Brant; Xuhang Li
OBJECTIVE:u2003 6‐mercaptopurine (6‐MP) is efficacious in the treatment of inflammatory bowel disease (IBD). However, about one‐third of patients respond poorly to therapy. This study aimed to characterize the inherent differences in 6‐MP transport that may cotribute to the differences in treatment responses.
Inflammation Research | 2016
Jesse M. Damsker; Laurie S. Conklin; Soheil Sadri; Blythe C. Dillingham; Karuna Panchapakesan; Christopher R. Heier; John M. McCall; Anthony D. Sandler
Objective and designThe goal of this study was to assess the capacity of VBP15, a dissociative steroidal compound, to reduce pro-inflammatory cytokine expression in vitro, to reduce symptoms of colitis in the trinitrobenzene sulfonic acid-induced murine model, and to assess the effect of VBP15 on growth stunting in juvenile mice.MaterialsIn vitro studies were performed in primary human intestinal epithelial cells. Colitis was induced in mice by administering trinitrobenzene sulfonic acid. Growth stunting studies were performed in wild type outbred mice.TreatmentCells were treated with VBP15 or prednisolone (10xa0μM) for 24xa0h. Mice were subjected to 3xa0days of VBP15 (30xa0mg/kg) or prednisolone (30xa0mg/kg) in the colitis study. In the growth stunting study, mice were subjected to VBP15 (10, 30, 45xa0mg/kg) or prednisolone (10xa0mg/kg) for 5xa0weeks.MethodsCytokines were measured by PCR and via Luminex. Colitis symptoms were evaluated by assessing weight loss, intestinal blood, and stool consistency. Growth stunting was assessed using an electronic caliper.ResultsVBP15 significantly reduced the in vitro production of CCL5 (pxa0<xa00.001) IL-6 (pxa0<xa00.001), IL-8 (pxa0<xa00.05) and reduced colitis symptoms (pxa0<xa00.05). VBP15 caused less growth stunting than prednisolone (pxa0<xa00.001) in juvenile mice.ConclusionVBP15 may reduce symptoms of IBD, while decreasing or avoiding detrimental side effects.
Nature Reviews Gastroenterology & Hepatology | 2017
Alex J. Thompson; Michael D. Hughes; Salzitsa Anastasova; Laurie S. Conklin; Tudor Thomas; Cadman L. Leggett; William A. Faubion; Thomas J. Miller; Peter Delaney; Francois Lacombe; Sacha Loiseau; Alexander Meining; Rebecca Richards-Kortum; Guillermo J. Tearney; Paul Kelly; Guang-Zhong Yang
Environmental enteric dysfunction (EED) is a disease of the small intestine affecting children and adults in low and middle income countries. Arising as a consequence of repeated infections, gut inflammation results in impaired intestinal absorptive and barrier function, leading to poor nutrient uptake and ultimately to stunting and other developmental limitations. Progress towards new biomarkers and interventions for EED is hampered by the practical and ethical difficulties of cross-validation with the gold standard of biopsy and histology. Optical biopsy techniques — which can provide minimally invasive or noninvasive alternatives to biopsy — could offer other routes to validation and could potentially be used as point-of-care tests among the general population. This Consensus Statement identifies and reviews the most promising candidate optical biopsy technologies for applications in EED, critically assesses them against criteria identified for successful deployment in developing world settings, and proposes further lines of enquiry. Importantly, many of the techniques discussed could also be adapted to monitor the impaired intestinal barrier in other settings such as IBD, autoimmune enteropathies, coeliac disease, graft-versus-host disease, small intestinal transplantation or critical care.
Inflammatory Bowel Diseases | 2017
Dror S. Shouval; Liza Konnikova; Alexandra Griffith; Sarah Wall; Amlan Biswas; Lael Werner; Moran Nunberg; Jochen Kammermeier; Jeremy A. Goettel; Rajsavi Anand; Hannah Chen; Batia Weiss; Jian Li; Anthony Loizides; Baruch Yerushalmi; Tadahiro Yanagi; Rita Beier; Laurie S. Conklin; Christen L. Ebens; Fernanda Stephanie Santos; Mary Sherlock; Jeffery D. Goldsmith; Daniel Kotlarz; Sarah C. Glover; Neil P. Shah; Athos Bousvaros; Holm H. Uhlig; Aleixo M. Muise; Christoph Klein; Scott B. Snapper
Background: IL10 receptor (IL10R) deficiency causes severe infantile-onset inflammatory bowel disease. Intact IL10R-dependent signals have been shown to be important for innate and adaptive immune cell functions in mice. We have previously reported a key role of IL10 in the generation and function of human anti-inflammatory macrophages. Independent of innate immune cell defects, the aim of the current study was to determine the role of IL10R signaling in regulating human CD4+ T-cell function. Methods: Peripheral blood mononuclear cells and intestinal biopsies cells were collected from IL10/IL10R-deficient patients and controls. Frequencies of CD4+ T-cell subsets, naive T-cell proliferation, regulatory T cell (Treg)-mediated suppression, and Treg and TH17 generation were determined by flow cytometry. Transcriptional profiling was performed by NanoString and quantitative real-time polymerase chain reaction. RNA in situ hybridization was used to determine the quantities of various transcripts in intestinal mucosa. Results: Analysis of 16 IL10- and IL10R-deficient patients demonstrated similar frequencies of peripheral blood and intestinal Tregs, compared with control subjects. In addition, in vitro Treg suppression of CD4+ T-cell proliferation and generation of Treg were not dependent on IL10R signaling. However, IL10R-deficient T naive cells exhibited higher proliferative capacity, a strong TH17 signature, and an increase in polarization toward TH17 cells, compared with controls. Moreover, the frequency of TH17 cells was increased in the colon and ileum of IL10R-deficient patients. Finally, we show that stimulation of IL10R-deficient Tregs in the presence of IL1&bgr; leads to enhanced production of IL17A. Conclusions: IL10R signaling regulates TH17 polarization and T-cell proliferation in humans but is not required for the generation and in vitro suppression of Tregs. Therapies targeting the TH17 axis might be beneficial for IL10- and IL10R-deficient patients as a bridge to allogeneic hematopoietic stem cell transplantation.